Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Bancroft
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 0.69
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -51.55
Financials
Net Income
$2.46MEBITDA
$2.48MFree Cash Flow
$-5.74MEPS (diluted)
$0.03Shares Outstanding (diluted)
89.96M+4564.8%Operating Expenses
$4.49MCash & Debt
$11.42MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-39.22M | $-3.95 |
| 2024 | $0.00 | $42.01M | $77.74 |
| 2023 | $0.00 | $-384.63M | $-744.83 |
| 2022 | $0.00 | $-52.56M | $-27.25 |
| 2021 | $0.00 | $-55.64M | $18.86 |
| 2020 | $2.52M | $-32.91M | $-0.01 |
| 2019 | $3.36M | $172.92M | $1481.04 |
Valuation
AEONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·6d ago·Neutral
AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Received FDA Type 2b feedback providing greater clarity on AEON's integrated biosimilar development strategy combining comparative analytical assessment, human pharmacodynamic studies, and a substantial body of existing comparative clinical evidence -
View source ↗ - Newsthenewswire.com·12d ago·Negative
Aeon Strategies Ltd. Provides Bi-Weekly MCTO Status Update TORONTO, ONTARIO – TheNewswire - November 10, 2026 (The Newswire) – AEON STRATEGIES LTD. (formerly Cloud3 Ventures Inc.) (CSE: AEON) (OTCQB: CLDVF) (FSE: WQ40) (the “ Company ” or “ Aeon ”) is providing this bi-weekly default status report under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). On October 23, 2026 and October 27, 2026, the Company announced that it expected to be unable to file its audited annual fi…
View source ↗ - Newsglobenewswire.com·13d ago·Negative
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450 Submission advances ABP-450 biosimilar development program following recent FDA Type 2b meeting
View source ↗ - Newsthenewswire.com·26d ago·Negative
AEON STRATEGIES LTD. Provides Update on Anticipated Late Filing of Annual Financial Statements TORONTO, ONTARIO – TheNewswire - October 27, 2026 — AEON STRATEGIES LTD. (formerly Cloud3 Ventures Inc.) (CSE: AEON) (OTCQB: CLDVF) (FSE: WQ40) (the “ Company ” or “ Aeon ”) provides an update to its news release dated October 23, 2026 (the “ Default Announcement ”) regarding the anticipated late filing of its audited annual financial statements for the year ended June 30, 2026, the related management'…
View source ↗ - Newsthenewswire.com·30d ago·Neutral
…nnounces Anticipated Late Filing of Annual Financial Statements and Application for Management Cease Trade Order TORONTO, ONTARIO – TheNewswire - October 23, 202 6 - AEON STRATEGIES LTD. (formerly Cloud3 Ventures Inc.) (CSE: AEON) (OTCQB:CLDVF)(FSE:WQ40) (the “ Company ” or “ Aeon ”) announces that it expects to be unable to file its audited annual financial statements for the year ended June 30, 2026, the related management's discussion and analysis and the related CEO and CFO certifications (c…
View source ↗ - Newsglobenewswire.com·53d ago·Negative
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026 AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined devel…
View source ↗ - Newsglobenewswire.com·83d ago·Positive
AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets'…
View source ↗ - Newsglobenewswire.com·90d ago·Neutral
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer - Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing A…
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® - Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program
View source ↗
Earnings
Mon, Mar 29(in 4 months)
Consensus estimate $-0.09 per share
Typical surprise +48.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.01 vs $-0.08beat
- Wed, Aug 12$-0.02 vs $-0.23beat
- Thu, May 14$-0.44 vs $-0.44beat
- Mon, Mar 30$-5.24 vs $-0.17miss
- Fri, Nov 14$-0.39 vs $-0.43beat
- Mon, Aug 11$-0.60 vs $-11.51beat
Estimates and results for AEON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AEON officers and directors.
- Bought
- $385k
- Sold
- $73.8m
7 trades
1 trade
- Wilson Alexander Blairbought
- Sy Jenniferbought
- Bancroft Robert E.bought
- Lynch Timothy Pbought
- Fischer Jostbought
- Fischer Jostbought
- Fischer Jostbought
- Strathspey Crown Holdings Group, Llcsold
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AEON.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
